Heron Therapeutics, Inc. provided net product sales guidance for the full year 2023. For the period, the company expected net product sales for the oncology care franchise to be in the range of $99 million to $103 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.67 USD | +10.88% | +25.04% | +115.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+115.88% | 499M | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Provides Net Product Sales Guidance for the Full Year 2023